| Name | Title | Contact Details |
|---|
Alpine Solutions is a pioneer in the medical industry for the repair and sales of electronics, imaging equipment, CT & MRI parts, medical drives and etc.
Equiscript helps safety net providers better understand and grow their 340B pharmacy business. With a keen eye for detail, our skilled people assist our clients in the design and implementation of a home delivery pharmacy program intended to improve health outcomes by putting much-needed medicines into the hands of those patients in the communities we serve.
Azurity Pharmaceuticals, Inc. is a privately held specialty pharmaceutical company focused on the needs of patients, especially children and the elderly, that require customized user-friendly drug formations. Our products have benefited millions of patients whose needs are not served by other commercially available therapies. AZURITY VALUES: COMPASSION - We put the needs of our patients and caregivers at the center of everything we do, including the decisions we make. QUALITY - We aim to provide our patients with the highest-quality, safe, and effective therapies for their needs. INNOVATION - We use the best science and manufacturing techniques to deliver cost-effective, high-value medications to our patients. A COMPANY OF DIFFERENCE MAKERS As Azurity grows to meet new challenges, and serve new patient groups, one thing never changes: our dedication to the lives of others. Whether through our innovative medications, our focus on creating a positive company environment, or our community and volunteer work, we are committed to having a positive impact on the lives of those we touch.
Artios is a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. The Company is led by an experienced leadership team with world class scientific capabilities and proven expertise in DDR drug discovery, including the identification and development of the PARP inhibitor olaparib. It has a unique partnership with Cancer Research UK (CRUK), and collaborations with leading DNA repair researchers worldwide, such as The Institute of Cancer Research (ICR), London, the Netherlands Cancer Institute (NKI) and The Francis Crick Institute, London. Artios is building a pipeline of next-generation DDR programmes to target hard to treat cancers which will move into Phase 1 clinical studies in 2021. These include ATR inhibitor ART0380 for treating DDR defective tumours and the first-in-class Pol theta inhibitor ART4215 for mono therapy and combination treatments. In December 2020, Artios entered into a global three-year strategic research collaboration with Merck KGaA, Darmstadt, Germany to identify and develop precision oncology medicines targeting nucleases. Artios is backed by blue chip investors including: AbbVie Ventures, Andera Partners, Arix Bioscience plc, IP Group plc, Life Science Partners (LSP), M Ventures, Novartis Venture Fund (NVF), Pfizer Ventures and SV Health Investors. Artios is based at the Babraham Research Campus in Cambridge, UK, with an office in New York City, USA.